
|Videos|February 9, 2017
FDA Approval and 2 Priority Reviews in Bladder Cancer, and ASCO's Cancer Advance of the Year
Advertisement
Episodes in this series
Gina Columbus reports on an FDA approval and 2 priority reviews in bladder cancer, highlights from the 2017 European Cancer Congress, a European approval in lung cancer, and ASCO announces its Cancer Advance of the Year.
Advertisement
Advertisement
Advertisement
Trending on OncLive
1
Breast Cancer Experts Spotlight Practice-Informing and Thought-Provoking Data From ASCO 2026
2
FDA Grants Priority Review to Giredestrant for ER-Positive Early Breast Cancer
3
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
4
Bispecific-Based Approaches Highlight Key Multiple Myeloma Data Set to Emerge at EHA 2026
5






























































